Clinical Trial Update: TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor Agonist Therapy [NA]

View source ↗

Summary

The clinical trial update indicates the TANTALUS Therapy trial for adults with Type 2 diabetes intolerant or inadequately responsive to GLP-1 receptor agonists …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• TANTALUS Therapy

Snippet

Sponsor: MetaCure (USA), Inc. | Conditions: Diabetes Mellitus, Type 2 | NA | Status: TERMINATED